si:ch211-283h6.4 Antibody

What is si:ch211-283h6.4 and what is its genomic organization?

Si:ch211-283h6.4 is a protein-coding gene located on chromosome 5 in the zebrafish (Danio rerio) genome, specifically at position 68816231-68826343 on build GRCz11 . It belongs to the "Uncharacterised protein family UPF0561" (IPR018888) . The gene produces an mRNA transcript (si:ch211-283h6.4-201) that has been annotated by Ensembl and is 495 nucleotides in length . The gene structure spans exon boundaries, with assays typically designed to cross the boundary between exons 2 and 3 . Current genomic databases indicate this gene has not been extensively characterized, with limited information available regarding its expression patterns, phenotypic effects, or interactions with other genes in standard databases.

How is si:ch211-283h6.4 related to human C2orf68?

Si:ch211-283h6.4 is orthologous to human C2orf68 (chromosome 2 open reading frame 68) . This orthology relationship suggests evolutionary conservation of function between zebrafish and humans, making si:ch211-283h6.4 potentially valuable for understanding human C2orf68 function through comparative studies. The protein encoded by si:ch211-283h6.4 is represented in UniProtKB as A3KQ58 . Like many orthologous relationships between zebrafish and human genes, this connection provides opportunities for using zebrafish as a model system to investigate conserved biological processes relevant to human health and disease, though specific disease associations have not yet been established for either gene.

What expression patterns have been observed for si:ch211-283h6.4 in zebrafish?

While comprehensive expression data for si:ch211-283h6.4 is limited, correlation analysis from single-cell RNA sequencing data provides insights into its potential expression patterns. The gene shows positive correlation with several genes involved in RNA processing and ribosome biogenesis, including hspb1 (r=0.071), fbl (r=0.065), hnrnpa1b (r=0.065), ncl (r=0.065), and nop58 (r=0.065) . Conversely, it shows negative correlation with genes expressed in muscle cells (mylpfa, r=-0.024) and epithelial cells (krt4, r=-0.034; krt5, r=-0.026) . This correlation pattern suggests si:ch211-283h6.4 may be involved in cellular processes related to RNA metabolism or nuclear functions, though direct experimental validation would be required to confirm these associations and specific expression domains.

What strategies are recommended for developing antibodies against si:ch211-283h6.4?

For poorly characterized proteins like si:ch211-283h6.4, multiple complementary approaches should be considered:

• Epitope prediction and peptide antibodies: Using bioinformatic tools to identify antigenic regions of the predicted protein sequence, focusing on hydrophilic, surface-exposed regions. Multiple peptide antigens (typically 15-20 amino acids) should be selected from different regions of the protein to increase success probability.

• Recombinant protein expression: Expressing the full-length protein or specific domains in bacterial or mammalian expression systems for immunization. The UniProtKB entry A3KQ58 can provide sequence information for designing expression constructs .

• Custom antibody services: Specialized providers like Cusabio offer custom antibody development services for zebrafish proteins , which may be particularly valuable for challenging targets like si:ch211-283h6.4.

• Multiple host species approach: Developing antibodies in different host species (rabbit, mouse, goat) to enable co-localization studies and provide flexibility in experimental applications.

The predicted protein family (UPF0561) information should be considered when designing immunogens to ensure specificity against conserved domains.

How can researchers validate antibodies for poorly characterized proteins like si:ch211-283h6.4?

Rigorous validation is crucial, especially for poorly characterized proteins:

• Western blotting: Verify the antibody detects a protein of the expected molecular weight (information derived from the 495 nt transcript would predict a protein of approximately 18 kDa) .

• Overexpression controls: Generate overexpression constructs of tagged si:ch211-283h6.4 to confirm antibody detection of the overexpressed protein.

• Knockdown/knockout validation: Use morpholinos, CRISPR-Cas9, or other gene editing technologies to reduce or eliminate target expression, confirming antibody signal reduction or loss.

• Preabsorption tests: Pre-incubate antibody with immunizing peptide or recombinant protein prior to immunostaining to demonstrate specificity.

• Cross-reactivity assessment: Test antibody against closely related proteins, particularly other members of the UPF0561 family , to ensure specificity.

• Mass spectrometry validation: Perform immunoprecipitation followed by mass spectrometry to confirm the antibody captures the intended target protein.

A combination of these approaches provides the strongest validation of antibody specificity.

What protocols are recommended for Western blotting with si:ch211-283h6.4 antibodies?

For Western blotting with si:ch211-283h6.4 antibodies, consider the following optimized protocol:

• Sample preparation:

  • Extract proteins from zebrafish tissues or cells using RIPA buffer with protease inhibitors

  • For developmental studies, collect embryos at multiple stages (e.g., 24, 48, 72 hpf)

  • Include positive controls (tissues with correlated gene expression, such as those expressing hspb1, fbl, or ncl)

• Gel electrophoresis and transfer:

  • Use 12-15% SDS-PAGE gels suitable for smaller proteins (expected size ~18 kDa based on transcript length)

  • Transfer to PVDF membranes at 100V for 1 hour or 30V overnight at 4°C

• Antibody incubation:

  • Block with 5% milk or BSA in TBST for 1 hour

  • Start with 1:500 dilution for untested antibodies, with overnight incubation at 4°C

  • Test multiple secondary antibodies conjugated to HRP or fluorescent labels

  • Include extensive washing steps (4-5x 5 minutes with TBST)

• Detection:

  • Use enhanced chemiluminescence for HRP-conjugated secondaries

  • For fluorescent secondaries, use appropriate imaging systems with multiple channels

• Controls:

  • Include positive and negative tissue controls based on correlation data

  • Run knockdown/knockout samples alongside wild-type samples

  • Consider loading controls targeting housekeeping proteins (β-actin, GAPDH)

How can si:ch211-283h6.4 antibodies be applied in immunohistochemistry (IHC) experiments?

For IHC applications with si:ch211-283h6.4 antibodies:

• Tissue preparation:

  • Fix zebrafish embryos/tissues in 4% PFA for 2-4 hours at room temperature or overnight at 4°C

  • Process for paraffin embedding or cryosectioning (10-12 μm sections)

  • For whole-mount immunostaining, perform additional permeabilization steps

• Antigen retrieval:

  • Test multiple methods (citrate buffer pH 6.0, EDTA buffer pH 8.0, enzymatic retrieval)

  • Heat-induced epitope retrieval: microwave or pressure cooker for 10-20 minutes

• Antibody incubation:

  • Block with 5-10% normal serum (species of secondary antibody) with 0.1-0.3% Triton X-100

  • Incubate with primary antibody at 1:100-1:500 dilution overnight at 4°C

  • Use fluorescent secondary antibodies for co-localization studies

• Controls and validation:

  • Include peptide competition controls

  • Perform parallel experiments with multiple antibodies targeting different epitopes

  • Include tissues expected to express si:ch211-283h6.4 based on correlation data

• Analysis:

  • Use confocal microscopy for precise localization

  • Consider co-staining with markers for subcellular compartments (nuclear, nucleolar, etc.)

  • Quantify expression patterns across different tissues and developmental stages

How can researchers investigate potential functions of si:ch211-283h6.4 based on correlated gene expression?

The gene correlation data provides valuable insights for functional investigations:

• Pathway analysis based on correlated genes:

  • The strongest positive correlations with si:ch211-283h6.4 include genes involved in RNA processing and ribosome biogenesis (fbl, r=0.065; ncl, r=0.065; nop58, r=0.065; npm1a, r=0.064; dkc1, r=0.063)

  • These correlations suggest potential involvement in nucleolar functions, rRNA processing, or ribosome assembly

• Co-expression network analysis:

  • Construct functional networks using the top correlated genes (both positive and negative)

  • Tools like STRING or Cytoscape can identify enriched biological processes

  • The correlation with genes like hnrnpa1b (r=0.065), npm1a (r=0.064), and nop56 (r=0.061) suggests RNA metabolism functions

• Comparative studies with human C2orf68:

  • Leverage orthology relationship to human C2orf68

  • Examine available human cell line data for C2orf68 to complement zebrafish studies

  • Use phylogenetic profiling to identify conserved functional relationships

• Subcellular localization prediction:

  • Based on correlated genes (ncl, npm1a) , investigate potential nucleolar localization

  • Design experiments to determine if si:ch211-283h6.4 co-localizes with nucleolar markers

This correlation-based approach provides a data-driven foundation for hypothesis generation about si:ch211-283h6.4 function.

What gene editing approaches are suitable for studying si:ch211-283h6.4 function?

Several gene editing strategies can be employed:

These approaches should be combined with the correlated gene expression data to assess effects on potentially related biological pathways.

What controls should be implemented when using si:ch211-283h6.4 antibodies?

Robust controls are essential for reliable results:

• Genetic controls:

  • CRISPR knockout or morpholino knockdown samples

  • Overexpression systems with tagged constructs

  • Heterozygous vs. homozygous mutant comparisons

• Technical controls:

  • Primary antibody omission

  • Isotype controls (matched concentration of non-specific IgG)

  • Secondary antibody-only controls

  • Peptide competition/preabsorption controls

• Tissue controls:

  • Positive controls: tissues with expected expression based on correlation data (tissues expressing hspb1, fbl, ncl)

  • Negative controls: tissues with anti-correlated gene expression (tissues expressing pvalb1, cyt1, krt4)

• Procedural controls:

  • Multiple fixation and antigen retrieval methods

  • Concentration gradients for antibody optimization

  • Biological replicates across different zebrafish clutches

• Signal validation:

  • Dual labeling with antibodies against different epitopes

  • Correlation with mRNA expression (in situ hybridization)

  • Correlation with tagged protein expression patterns

Implementing this comprehensive control system will ensure reliable interpretation of si:ch211-283h6.4 antibody results.

How can researchers address non-specific binding issues with si:ch211-283h6.4 antibodies?

Non-specific binding is a common challenge, especially with antibodies against poorly characterized proteins:

• Optimization strategies:

  • Titrate antibody concentrations (test 1:100 to 1:5000 dilutions)

  • Modify blocking conditions (increase BSA/milk percentage to 5-10%)

  • Increase washing duration and frequency (5-6 washes, 10 minutes each)

  • Add detergents (0.1-0.3% Triton X-100) to reduce hydrophobic interactions

  • Test different fixation protocols that may better preserve epitopes

• Cross-reactivity reduction:

  • Pre-absorb antibody with zebrafish tissue lysates from knockout animals

  • Increase blocking time (overnight at 4°C)

  • Add competing proteins (1% BSA, 5% milk) during antibody incubation

  • Use monovalent antibody fragments (Fab) to reduce non-specific binding

• Signal-to-noise enhancement:

  • Employ tyramide signal amplification for low-abundance targets

  • Use directly labeled primary antibodies to eliminate secondary antibody cross-reactivity

  • Optimize imaging parameters (exposure, gain, offset) to distinguish specific signal

• Validation approaches:

  • Compare multiple antibodies against different epitopes

  • Correlate antibody signal with mRNA expression patterns

  • Verify signal reduction in knockdown/knockout samples

These strategies should be systematically tested and documented to establish optimal conditions for si:ch211-283h6.4 detection.

How might understanding si:ch211-283h6.4 function contribute to broader research areas?

The study of si:ch211-283h6.4 has several promising implications:

• Evolutionary conservation of UPF0561 family proteins:

  • Investigate functional conservation between zebrafish si:ch211-283h6.4 and human C2orf68

  • Compare with other UPF0561 family members across species

  • Explore potential conserved roles in fundamental cellular processes

• RNA metabolism and ribosome biogenesis:

  • Based on correlation with genes like fbl, ncl, and nop58 , explore potential roles in:

    • rRNA processing

    • Ribosome assembly

    • Nucleolar function

    • Stress response pathways

• Developmental biology applications:

  • Map expression patterns throughout zebrafish development

  • Identify critical periods where si:ch211-283h6.4 function may be essential

  • Explore potential roles in tissue-specific differentiation

• Translational research potential:

  • Investigate whether mutations in human C2orf68 associate with disease

  • Develop zebrafish models of human C2orf68 dysfunction

  • Explore whether si:ch211-283h6.4/C2orf68 function relates to cancers or developmental disorders

This multifaceted approach connects fundamental science with potential biomedical applications, leveraging the zebrafish model system's unique advantages.

What high-throughput approaches could advance our understanding of si:ch211-283h6.4?

Several cutting-edge technologies could accelerate research:

• Proteomics approaches:

  • BioID or APEX proximity labeling to identify protein interaction partners

  • IP-MS using validated si:ch211-283h6.4 antibodies

  • Crosslinking mass spectrometry to identify transient interactions

  • Correlation with the positive interaction network (hspb1, fbl, hnrnpa1b)

• Transcriptomics integrations:

  • RNA-seq following si:ch211-283h6.4 knockout/knockdown

  • Single-cell RNA-seq to refine expression domains

  • ATAC-seq to identify potential regulatory elements

  • ribosome profiling to assess translation impacts

• Functional genomics screens:

  • CRISPR screens to identify genetic interactors

  • Chemical genetic screens to identify small molecule modulators

  • Suppressor/enhancer screens in si:ch211-283h6.4 mutant backgrounds

• Structural biology approaches:

  • Cryo-EM or X-ray crystallography of the UPF0561 domain

  • Integrative structural modeling using crosslinking data

  • Structure prediction using AlphaFold or similar tools

These approaches, particularly when informed by the gene correlation data , would rapidly expand our understanding of si:ch211-283h6.4 function beyond what traditional approaches could achieve.